RUBY - Rubius Therapeutics,...

Rubius Therapeutics, Inc.

RUBY

NASDAQ

Inactive Equity

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

0.057 USD

0.0015 (2.63%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

PPE Schedule

Year

2022

2021

2020

2019

Gross PPE

2.83M

86.63M

94.4M

103.48M

Annual Depreciation

6.25M

7.72M

5.69M

Capital Expenditure

-5.3M

-3.65M

-5.5M

-40.66M

Net PPE

1.88M

82.55M

94.2M

141.15M

All figures are in USD.

All Income Statement Balance Sheet Statement Cash Flow Statement Retained Earning Schedule PPE Schedule Intangible and Goodwill Schedule

FMP

Home Terms of Service Privacy Policy Blog Careers FAQs Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.